Overview

Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and severe COPD Secondary endpoints: pharmacokinetics, pharmacodynamics (effect on lung function), safety and tolerability

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Tiotropium Bromide